Menopause drug made in Canada won’t be available to Canadians, but still sold in U.S.
TORONTO — Canadian women will no longer have access to a menopause drug that is made in Canada, even though the drugmaker plans to continue producing it for patients in the United States.
Pfizer has discontinued Premarin estrogen tablets and vaginal cream, used for decades to treat menopausal and post-menopausal symptoms such as hot flashes, night sweats, vaginal burning and dryness, abnormal uterine bleeding, and osteoporosis prevention.
The active ingredient, conjugated equine estrogen, comes from pregnant mares’ urine collected at 12 family-owned ranches in Manitoba and Saskatchewan since the early 1940s.
Pfizer discontinued the vaginal cream for Canadians in early November citing “business reasons.” The company says the tablet will be off the market starting next year in June.
Meanwhile, ranchers in the prairies will continue to collect the raw ingredients, brought to a manufacturing facility in Brandon, Man., where estrogen is extracted, says Norman Luba, executive director of the region’s equine ranching association.
Pfizer Canada’s senior communications manager Sophie Morin said the products have become “commercially unsustainable” for the drugmaker to keep supplying to Canadians.
The decision was not “driven solely by the pricing conditions for Premarin in Canada,” Morin said, also citing manufacturing and supply costs, the pricing and reimbursement environment, and the ability to maintain sustainable supply over the longer term.
Dr. Jennifer Gunter, a gynecologist from Manitoba based in the United States, wrote on her Substack that the price of a tube of Premarin cream in Canada is about C$50, while the same tube in the U.S. sells for approximately US$400 to $500.
Gunter urged Canadians to be concerned about Pfizer’s decision, listing several reasons, including that limiting medication is never good for women. She also says Premarin has been shown to reduce the risk of breast cancer, and it is covered by provincial drug plans.
“This isn’t just about Premarin. Every Canadian who cares about access to medications needs to be engaged and speak up,” Gunter wrote.
Menopause expert Dr. Michelle Jacobson said it feels wrong that she won’t be able to prescribe Premarin to her patients, despite the fact that this is a drug that comes from Canada.
“Globally, it is, the supply chain starts in Canada, and yet, for reasons that are not completely transparent, Canadians are now not going to be able to access this homegrown raw material,” Jacobson said.
In response to concerns from physicians and patients, Marin said Pfizer understands, and recognizes “changes in the availability of a medicine can be difficult for those who rely on it.”
Health Canada says it is assessing the impact of the discontinuation and collaborating with clinical and pharmacy stakeholders to support continuity of care. The regulator also put out a notice on Thursday about a shortage of Premarin Intravenous for abnormal uterine bleeding associated with hormonal imbalance, expected to last from December to May due to a manufacturing disruption.
PUBLIC HEALTH PLANS AND PREMARIN CREAM
Some provincial public health plans, for instance Ontario, covered Pfizer’s Premarin cream but not the alternative cream on the market.
Lily Barnes, a spokesperson for the ministry of health in Ontario, says there are other estrogen drug products covered by the province’s drug benefits, such as a vaginal ring, tablet and insert.
However, Jacobson says the active ingredients are different in those products. She also says the vaginal cream can be better for certain conditions, such as dryness.
Meanwhile, Alberta’s ministry of health says that as a result of Pfizer’s move it is adding Estragyn vaginal cream, made by Searchlight Pharma, to the province’s drug benefit list to ensure women still have access.
A spokesperson said it is a temporary measure the ministry plans to make permanent. Quebec and Manitoba’s provincial drug benefits already cover the alternative.
PRODUCTION SEASON UNDERWAY ON RANCHES
Luba, executive director of the North American Equine Ranching Information Council, said the Canadian ranchers are proud of what they do, and while there might be “some disappointment,” it’s ultimately the company’s decision.
He said the ranchers are busy as their production season gets underway this week.
That means bringing horses into the barn, collecting their urine, and storing it in a steel bulk tank until a truck comes to pick it up, similar to a dairy cow production.
“I’ve often said it’s a great partnership between women’s health care and rural Canadian agriculture,” Luba said.
This report by The Canadian Press was first published Nov. 19, 2026.
Canadian Press health coverage receives support through a partnership with the Canadian Medical Association. CP is solely responsible for this content.
Hannah Alberga, The Canadian Press
Comments